A phase 2 study of ALIMTA [pemetrexed] in solid tumor patients with stable third-space fluid.
Latest Information Update: 06 Sep 2021
Price :
$35 *
At a glance
- Drugs Pemetrexed (Primary)
- Indications Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 01 Apr 2009 Actual patient number (31) added and primary outcome amended as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.